81 related articles for article (PubMed ID: 22936671)
1. Barriers to hepatitis C treatment.
McGowan CE; Fried MW
Liver Int; 2012 Feb; 32 Suppl 1(0 1):151-6. PubMed ID: 22212587
[TBL] [Abstract][Full Text] [Related]
2. Big changes are coming in hepatitis C.
Poordad F
Curr Gastroenterol Rep; 2011 Feb; 13(1):72-7. PubMed ID: 21063814
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C: the end of the beginning and possibly the beginning of the end.
Alter HJ; Liang TJ
Ann Intern Med; 2012 Feb; 156(4):317-8. PubMed ID: 22351718
[No Abstract] [Full Text] [Related]
4. From hepatitis A to E: A critical review of viral hepatitis.
Castaneda D; Gonzalez AJ; Alomari M; Tandon K; Zervos XB
World J Gastroenterol; 2021 Apr; 27(16):1691-1715. PubMed ID: 33967551
[TBL] [Abstract][Full Text] [Related]
5. Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial.
Heidrich B; Cordes HJ; Klinker H; Möller B; Naumann U; Rössle M; Kraus MR; Böker KH; Roggel C; Schuchmann M; Stoehr A; Trein A; Hardtke S; Gonnermann A; Koch A; Wedemeyer H; Manns MP; Cornberg M
PLoS One; 2015; 10(6):e0128069. PubMed ID: 26057627
[TBL] [Abstract][Full Text] [Related]
6. Simeprevir: a review of its use in patients with chronic hepatitis C virus infection.
Sanford M
Drugs; 2015 Feb; 75(2):183-96. PubMed ID: 25559421
[TBL] [Abstract][Full Text] [Related]
7. Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.
Sølund C; Krarup H; Ramirez S; Thielsen P; Røge BT; Lunding S; Barfod TS; Madsen LG; Tarp B; Christensen PB; Gerstoft J; Laursen AL; Bukh J; Weis N;
PLoS One; 2014; 9(12):e113034. PubMed ID: 25438153
[TBL] [Abstract][Full Text] [Related]
8. Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA.
Heidrich B; Wiegand SB; Buggisch P; Hinrichsen H; Link R; Möller B; Böker KH; Teuber G; Klinker H; Zehnter E; Naumann U; Busch HW; Maasoumy B; Baum U; Hardtke S; Manns MP; Wedemeyer H; Petersen J; Cornberg M;
PLoS One; 2014; 9(10):e108751. PubMed ID: 25302676
[TBL] [Abstract][Full Text] [Related]
9. PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis C.
Markova AA; Mihm U; Schlaphoff V; Lunemann S; Filmann N; Bremer B; Berg T; Sarrazin C; Zeuzem S; Manns MP; Cornberg M; Herrmann E; Wedemeyer H
PLoS One; 2014; 9(4):e94512. PubMed ID: 24751903
[TBL] [Abstract][Full Text] [Related]
10. [Which treatment options are validated for chronic viral hepatitis?].
Höner zu Siederdissen C; Manns MP; Cornberg M
Internist (Berl); 2013 Dec; 54(12):1427-8, 1430-3. PubMed ID: 24258199
[TBL] [Abstract][Full Text] [Related]
11. Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.
Colombo M; Fernández I; Abdurakhmanov D; Ferreira PA; Strasser SI; Urbanek P; Moreno C; Streinu-Cercel A; Verheyen A; Iraqi W; DeMasi R; Hill A; Läuffer JM; Lonjon-Domanec I; Wedemeyer H
Gut; 2014 Jul; 63(7):1150-8. PubMed ID: 24201995
[TBL] [Abstract][Full Text] [Related]
12. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting.
Maasoumy B; Port K; Markova AA; Serrano BC; Rogalska-Taranta M; Sollik L; Mix C; Kirschner J; Manns MP; Wedemeyer H; Cornberg M
PLoS One; 2013; 8(2):e55285. PubMed ID: 23383319
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C in 2012: On the fast track towards IFN-free therapy for hepatitis C?
Wedemeyer H
Nat Rev Gastroenterol Hepatol; 2013 Feb; 10(2):76-8. PubMed ID: 23296251
[No Abstract] [Full Text] [Related]
14. New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye.
Dusheiko G; Wedemeyer H
Gut; 2012 Dec; 61(12):1647-52. PubMed ID: 22936671
[No Abstract] [Full Text] [Related]
15. The dilemma for patients with chronic hepatitis C: treat now or warehouse?
Alberti A; Colombo M; Craxì A; Rizzetto M
Dig Liver Dis; 2014 Jan; 46(1):27-9. PubMed ID: 24268949
[No Abstract] [Full Text] [Related]
16. [Treatment of chronic hepatitis viral C: new associations].
Ouzan D
Presse Med; 2013 Jun; 42(6 Pt 1):977-82. PubMed ID: 23021659
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C drug development at a crossroads.
Nelson DR
Hepatology; 2009 Oct; 50(4):997-9. PubMed ID: 19787813
[No Abstract] [Full Text] [Related]
18. Protease inhibitors: silver bullets for chronic hepatitis C infection?
Alkhouri N; Zein NN
Cleve Clin J Med; 2012 Mar; 79(3):213-22. PubMed ID: 22383557
[TBL] [Abstract][Full Text] [Related]
19. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Asselah T; Marcellin P
Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
